Novo Nordisk A/S (NVO)
| Market Cap | 264.73B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 15.14 |
| Forward PE | 16.23 |
| Dividend | $1.23 (2.06%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 15,362,628 |
| Open | 59.00 |
| Previous Close | 58.74 |
| Day's Range | 58.45 - 60.10 |
| 52-Week Range | 45.05 - 120.56 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 85.25 (+42.97%) |
| Earnings Date | Nov 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $85.25, which is an increase of 42.97% from the latest price.
News
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
Novo plans online launch for obesity pill once approved, Bloomberg News reports
Danish drugmaker Novo Nordisk said it plans to make its new obesity pill available through telehealth platforms like Ro and WeightWatchers once it gets U.S. approval, Bloomberg News reported on Friday...
Novo Nordisk Is Primed For A Post-Earnings Recovery (Earnings Preview)
Novo Nordisk's Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and Alzhei...
Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says
HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thu...
The Truth About Novo Nordisk: 4 Myths That Don't Hold Up
Novo Nordisk remains a strong buy despite recent market pessimism, with key growth catalysts on the horizon. NVO's Wegovy, especially at higher doses, rivals Eli Lilly's Zepbound in weight loss and of...
LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers
Telehealth firm LifeMD said on Tuesday it would collaborate with Novo Nordisk to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including those who are insured and whose ...
Here's Why Morgan Stanley Analysts Downgraded Novo Nordisk's Stock
An analyst's concerns about demand for Novo Nordisk's blockbuster weight-loss drugs is weighing on the drugmaker's shares to start the week.
NVO Slides on Morgan Stanley Downgrade, Case for Value Trade
Morgan Stanley now holds the most pessimistic view of Novo Nordisk's (NVO) stock. It downgraded the company to underweight from equal weight and set a Street-low price target of $47.
Novo Nordisk Stock Is Downgraded. There's a ‘Tough Path Ahead.
U.S. prescriptions for Novo's Ozempic and Wegovy drugs are stagnating, Morgan Stanley analysts said.
NVO Downgrade Sell-Off, Defense Rally, CCL Cruises on Earnings
Carnival (CCL) cruised on an earnings beat and optimism for strong demand ahead. Diane King Hall takes a closer look at the report to show other strengths boosting the cruise line's pocketbook.
Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating
Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is likely to fail, as it set the most pessimistic target price foreca...
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
Novo Nordisk: Wegovy Sales Soar, Trump Tariffs No Threat
Despite the difficulties Novo Nordisk's GLP-1 franchise has encountered due to Eli Lilly and manufacturers of compounded versions of semaglutide, demand for Wegovy remains strong. So, its sales amount...
DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025
PHILADELPHIA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”) on beh...
Denmark's 'Novo Town' holds its breath as Wegovy fever fades
In Denmark's seaside town of Kalundborg, also known as "Novo Town", therapist Heidi Thron Rune has learnt to live with the noise of building work as new facilities take shape to meet demand for Novo N...
LLY & NVO Lead "Very Early Stages" of GLP-1 Market, PFE Reenters
Scott Zari says we're in the "very early stages" of the weight loss market. He points to Eli Lilly (LLY) as the market leader but notes Novo Nordisk (NVO) as a strong competitor, especially as it deve...
Here Are 2 Defensive Positions That Are Worth A Look Now
The market will likely pull back at some point, and I think it is smart to start considering some more defensive value positions in your portfolio. NVO remains one of the leaders in the diabetes and o...
Ozempic's Maker Got Crushed. The Rebound Is Under Way.
With a weight-loss pill on the horizon and the FDA's signal of a tougher stance on compounded knockoffs, Novo Nordisk might be turning a corner.
Cost will be key for Novo Nordisk's Wegovy pill, says Dr. Patel
CNBC's “Fast Money” team discusses new obesity drug data and the market leaders, including Novo Nordisk and Eli Lilly, with Dr. Kavita Patel, NBC News and MSNBC medical contributor.
Novo Nordisk: Don't Be Deterred By Outlook Downgrades
Novo Nordisk A/S's repeated downgrades in outlook might spook investors, but here I argue that there's still much to like about it. Stemming from a restructuring plan, if the latest outlook reduction ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Inside the Race to Launch GLP-1 Weight-Loss Pills
Plus, solar cars, Meta's new glasses and AI financial agents, in this edition of The Future of Everything newsletter.
Wall Street Breakfast Podcast: FedEx Delivers Earnings Surprise
FedEx (FDX) surges after beating FQ1 earnings expectations, reporting revenue growth, and advancing its FedEx Freight spin-off, targeted for June 2026. Cracker Barrel (CBRL) faces renewed activist pre...